Novel Treatment Approaches with mAbs Targeting Amyloid Deposits: Insights from VITAL
A panel of expert oncologists explore novel therapies using monoclonal antibodies designed to target amyloid deposit, highlighting key data from the VITAL study.
EP: 1.Exploring the Landscape Surrounding Light Chain Amyloidosis
EP: 2.Expert Perspectives on Differentiating Signs and Symptoms in AL Amyloidosis Diagnosis
EP: 3.Exploring Diagnostic Approaches for Patients with Light Chain Amyloidosis
EP: 4.Current Treatment Landscape for AL Amyloidosis
EP: 5.Unmet Needs and Treatment Considerations in Managing AL Amyloidosis
EP: 6.Treatment Strategies Using Monoclonal Antibodies in AL Amyloidosis
EP: 7.Optimizing Treatment Management Strategies in AL Amyloidosis with CD38-Directed mAbs
EP: 8.Addressing Challenges in Managing AL Amyloidosis with Cardiac Involvement
EP: 9.The Role of Cardiac Staging in Patients with AL Amyloidosis
EP: 10.Novel Treatment Approaches with mAbs Targeting Amyloid Deposits: Insights from VITAL
EP: 11.AFFIRM-AL: Birtamimab in Patients with Mayo Stage IV AL Amyloidosis
EP: 12.Expert Insights on Pooled Safety Data from the PRONTO and VITAL trials
EP: 13.The Potential Role of CAR T Therapy in AL Amyloidosis
EP: 14.NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis
EP: 15.Looking Ahead: Future Perspectives on AL Amyloidosis
This is a video synopsis/summary of a Peer Exchange involving Heather Landau, MD; Vaishali Sanchorawala, MD; and Jeffrey Zonder, MD.
The discussion focuses on promising developments in amyloidosis treatment, particularly the amyloid-busting agents. Two notable monoclonal antibodies (mAbs) in advanced development are highlighted: CAEL-101 and birtamimab. CAEL-101 targets the end terminus of kappa and lambda light chains, attaching to amyloid fibril deposits in phase 3 trials involving stage 3A and 3B patients. The results, expected in 2024, hold promise for advancing amyloidosis treatment. Birtamimab, directed at the C terminus of kappa and lambda light chains, dissolves amyloid deposits and soluble oligomers. Despite the VITAL study being halted for futility analysis, post hoc analysis revealed a favorable all-cause mortality outcome at 9 months for birtamimab in combination with standard care treatment. These antifibrillar antibodies represent innovative approaches in the evolving landscape of amyloidosis therapeutics.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
